Published in Arch Oral Biol on July 24, 2014
Nicotine Exposure During Pregnancy Results in Persistent Midline Epithelial Seam With Improper Palatal Fusion. Nicotine Tob Res (2015) 0.75
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 15.75
Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet (1995) 4.77
Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet (1995) 4.46
Cleft lip and palate. Lancet (2009) 4.29
TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol (1996) 3.29
Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J (2001) 3.24
Palate development. Development (1988) 2.80
Conditional inactivation of Tgfbr2 in cranial neural crest causes cleft palate and calvaria defects. Development (2003) 2.78
Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science (1999) 2.72
Molecular control of secondary palate development. Dev Biol (2006) 2.37
Cell autonomous requirement for Tgfbr2 in the disappearance of medial edge epithelium during palatal fusion. Dev Biol (2006) 1.79
Ectodermal Smad4 and p38 MAPK are functionally redundant in mediating TGF-beta/BMP signaling during tooth and palate development. Dev Cell (2008) 1.61
Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol (2003) 1.59
Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis (2007) 1.51
Roles for the type III TGF-beta receptor in human cancer. Cell Signal (2010) 1.50
Epithelial and ectomesenchymal role of the type I TGF-beta receptor ALK5 during facial morphogenesis and palatal fusion. Dev Biol (2006) 1.50
Medial edge epithelial cell fate during palatal fusion. Dev Biol (2000) 1.46
Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet (2003) 1.44
Transforming growth factor-beta3 regulates transdifferentiation of medial edge epithelium during palatal fusion and associated degradation of the basement membrane. Dev Dyn (1997) 1.42
TGF-beta3-induced palatogenesis requires matrix metalloproteinases. Mol Biol Cell (2001) 1.42
Modulation of noncanonical TGF-β signaling prevents cleft palate in Tgfbr2 mutant mice. J Clin Invest (2012) 1.37
Epithelial-mesenchymal transformation during palatal fusion: carboxyfluorescein traces cells at light and electron microscopic levels. Development (1992) 1.28
Antibodies to the Type II TGFbeta receptor block cell activation and migration during atrioventricular cushion transformation in the heart. Dev Biol (1996) 1.26
Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem (2001) 1.13
Overexpression of Smad2 in Tgf-beta3-null mutant mice rescues cleft palate. Dev Biol (2005) 1.07
The role of twist during palate development. Dev Dyn (2008) 1.05
Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J (2001) 1.05
The mechanism of TGF-β signaling during palate development. Oral Dis (2011) 1.04
TGF-beta3-dependent SMAD2 phosphorylation and inhibition of MEE proliferation during palatal fusion. Dev Dyn (2003) 1.00
An update on the aetiology of orofacial clefts. Hong Kong Med J (2004) 0.99
Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease. J Dent Res (2006) 0.98
Regulation of epithelial-mesenchymal transition in palatal fusion. Exp Biol Med (Maywood) (2009) 0.95
The TGF-beta type III receptor is localized to the medial edge epithelium during palatal fusion. Int J Dev Biol (2000) 0.94
Inhibition of SMAD2 expression prevents murine palatal fusion. Dev Dyn (2006) 0.93
Development of secondary palate requires strict regulation of ECM remodeling: sequential distribution of RECK, MMP-2, MMP-3, and MMP-9. Cell Tissue Res (2010) 0.92
Mechanisms of palatal epithelial seam disintegration by transforming growth factor (TGF) beta3. Dev Biol (2007) 0.91
Molecular and morphologic changes during the epithelial-mesenchymal transformation of palatal shelf medial edge epithelium in vitro. Int J Dev Biol (1991) 0.89
Temporospatial distribution of matrix metalloproteinase and tissue inhibitors of matrix metalloproteinases during murine secondary palate morphogenesis. Anat Embryol (Berl) (2000) 0.89
Immunohistochemical localization of TGF-beta type II receptor and TGF-beta3 during palatogenesis in vivo and in vitro. Int J Dev Biol (1998) 0.89
TGF-β-activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells. J Biol Chem (2013) 0.87
Functional role of transforming growth factor-beta type III receptor during palatal fusion. Dev Dyn (2007) 0.85
Signaling through Tgf-beta type I receptor Alk5 is required for upper lip fusion. Mech Dev (2008) 0.78
The expression of TGF-β3 for epithelial-mesenchyme transdifferentiated MEE in palatogenesis. J Mol Histol (2010) 0.77